Medicago
Quebec
About Medicago
Medicago Inc., a biotechnology company, focuses on the research, development, production, and commercialization of vaccines in Canada. The company develops its vaccines based on its proprietary technologies, including the plant-based Proficia technology and Virus-Like Particles (VLP) technology. Its product candidate includes H5N1 pandemic influenza VLP vaccine, which has completed a Phase I human clinical trial. The company is also developing H1N1 VLP vaccine for Influenza A/California/04/09 virus; and seasonal influenza vaccines. Medicago Inc. has collaboration agreements with Viridis S.A.; Genopole biopark to manufacture pandemic and seasonal influenza vaccines; and Philip Morris International to produce a therapeutic protein with a humancompatible glycosylation pattern. The company was incorporated in 1997 and is headquartered in Quebec City, Canada.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 501 – 1,000
- Estimated revenue: $50K – $100K
- Total funding: $208.1M
- Funding stage: M&A
- Last round: Grant (Oct 2020)
- Ticker: cve:MDG
- Website: medicago.com
- Phone: 4186586699
Industries & Categories
Biotechnology, Commercial, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/medicago-193640 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.